疫苗契约製造市场规模、份额和成长分析（按研发阶段、应用、工作流程、疫苗类型、产品类型、最终用户、服务类型和地区划分）—2026-2033年产业预测

全球疫苗契约製造市场预计到 2024 年将达到 30.4 亿美元，到 2025 年将达到 33 亿美元，到 2033 年将达到 63.3 亿美元，预测期（2026-2033 年）的复合年增长率为 8.5%。

市场趋势表明，全球疫苗契约製造行业正经历成长，这得益于疫苗接种倡议的扩大、技术的进步以及对疫情防范的重视。随着各国启动疫苗接种计划，疫苗生产需求预计将会增加，尤其是在中低收入国家。 mRNA和病毒载体等先进技术可望进一步推动市场发展。此外，各国政府和国际卫生组织为建设生产能力提供的财政支持将确保即使在危机时期也能维持供应链的韧性。然而，基础设施成本上升、法规环境严格、熟练劳动力短缺以及供应链脆弱性等挑战可能会阻碍市场渗透。总体而言，在营运效率提高和市场压力不断增加的背景下，该产业蕴藏着巨大的产生收入潜力。

全球疫苗契约製造市场的驱动因素

全球疫苗契约製造市场的主要驱动因素之一是疫苗需求的不断增长，而这又受到感染疾病发病率上升和人们对医疗保健日益重视的推动。新病原体和变种的出现，以及旨在根除疾病的全球卫生倡议，都催生了对快速且可扩展疫苗生产能力的需求。契约製造製造商凭藉其为成熟和新兴生物技术公司提供必要的专业知识、基础设施和柔软性，在满足这一需求方面占据了战略优势。这一趋势不仅提高了生产效率，还有助于疫苗的及时供应，从而推动了市场的整体成长。

全球疫苗契约製造市场面临的限制因素

全球疫苗契约製造领域的一大市场限制因素是疫苗生产监管环境的严格性。企业必须遵守卫生当局的严格合规要求，包括繁琐的测试和检验通讯协定，这可能导致延误和成本增加。此外，公共卫生政策的波动和复杂的智慧财产权问题也会阻碍製造商与製药公司之间的合作。不断提高的品质标准要求也迫使製造商在先进技术和熟练劳动力方面投入巨资，这给中小企业设置了障碍，并限制了新进入者的市场准入。

全球疫苗契约製造市场趋势

在全球疫苗契约製造市场，采用模组化和灵活的生产设施已成为一个显着趋势，从而提升了生产的灵活性和扩充性。供应商正越来越多地使用模组化洁净室、预製单元和一次性生物反应器，以满足多样化的生产需求，并确保对市场波动做出快速反应。这项策略转变支持多产品生产能力，使企业能够优化运营，加快新型疫苗的上市速度。这一趋势反映了整个行业对创新和效率的共同承诺，使契约製造製造商能够更好地应对不断变化的公共卫生需求和疫苗研发的动态环境。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球疫苗契约製造市场规模按阶段和复合年增长率划分（2026-2033 年）

• 临床前阶段
• 临床阶段
• 商业的

全球疫苗契约製造市场规模（按应用领域及复合年增长率划分）（2026-2033 年）

• 对人类而言
• 兽医

全球疫苗契约製造市场规模（按工作流程和复合年增长率划分）（2026-2033 年）

• 下游工艺
• 上游工程
• 其他的

全球疫苗契约製造市场规模（依疫苗类型划分）及复合年增长率（2026-2033 年）

• 减毒疫苗
• 灭活疫苗
• 基于次单元的
• 基于类毒素
• 基于DNA的

全球疫苗契约製造市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 病毒性的
• 细菌
• 其他的

全球疫苗契约製造市场规模（按产品类型和复合年增长率划分）（2026-2033 年）

• 单药疫苗
• 联合疫苗

全球疫苗契约製造市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 生物製药公司
• 研究机构和政府机构

全球疫苗契约製造市场规模（按服务类型和复合年增长率划分）（2026-2033 年）

• 填充和精加工
• 散装产品

全球疫苗契约製造市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Lonza Group（Switzerland）
• Catalent, Inc.（USA）
• Thermo Fisher Scientific Inc.（USA）
• Samsung Biologics Co., Ltd.（South Korea）
• WuXi Biologics（China）
• FUJIFILM Diosynth Biotechnologies（Japan）
• Emergent BioSolutions（USA）
• IDT Biologika GmbH（Germany）
• Charles River Laboratories（USA）
• AGC Biologics（USA）
• Boehringer Ingelheim BioXcellence（Germany）
• Recipharm AB（Sweden）
• CordenPharma（Germany）
• KBI Biopharma（USA）
• Merck KGaA（Germany）
• Curia Global, Inc.（USA）
• Siegfried Holding AG（Switzerland）
• Novasep（France）
• Richter-Helm BioLogics GmbH & Co. KG（Germany）
• Syngene International Limited（India）

结论与建议

Global Vaccine Contract Manufacturing Market size was valued at USD 3.04 Billion in 2024 and is poised to grow from USD 3.3 Billion in 2025 to USD 6.33 Billion by 2033, growing at a CAGR of 8.5% during the forecast period (2026-2033).

Market insights indicate that the global vaccine contract manufacturing sector is experiencing growth driven by increased vaccination initiatives, advancements in technology, and a focus on pandemic preparedness. The demand for vaccine manufacturing is anticipated to rise, particularly in low- and middle-income countries, as countries launch immunization programs. Cutting-edge technologies, including mRNA and viral vectors, are set to further enhance market development. Additionally, government and global health funding aimed at building manufacturing capacity will ensure a resilient supply chain during crises. However, challenges such as high infrastructure costs, stringent regulatory environments, a shortage of skilled labor, and supply chain vulnerabilities may hinder market penetration. Overall, the sector presents significant revenue generation potential amid rising operational efficiencies and market pressures.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccine Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccine Contract Manufacturing Market Segments Analysis

Global Vaccine Contract Manufacturing Market is segmented by Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type and region. Based on Phase, the market is segmented into Preclinical, Clinical and Commercial. Based on Application, the market is segmented into Human Use and Veterinary. Based on Workflow, the market is segmented into Downstream, Upstream and Others. Based on Vaccine Type, the market is segmented into Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based. Based on Type, the market is segmented into Viral, Bacterial and Others. Based on Product Type, the market is segmented into Single Vaccines and Combination Vaccines. Based on End User, the market is segmented into Biopharmaceutical Companies and Research Academies & Government Institutes. Based on Service Type, the market is segmented into Fill-Finish and Bulk Products. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vaccine Contract Manufacturing Market

One of the key market drivers for the Global Vaccine Contract Manufacturing Market is the increasing demand for vaccines, fueled by rising incidences of infectious diseases and the growing focus on preventive healthcare. The emergence of new pathogens and variants, coupled with global health initiatives aimed at eradicating diseases, necessitates rapid and scalable vaccine production capabilities. Contract manufacturers are strategically positioned to meet this demand, providing essential expertise, infrastructure, and flexibility for both established and emerging biotechnology firms. This trend not only enhances production efficiency but also supports timely vaccine distribution, thus driving the overall growth of the market.

Restraints in the Global Vaccine Contract Manufacturing Market

A significant market restraint for the global vaccine contract manufacturing sector is the stringent regulatory landscape governing vaccine production. Companies face rigorous compliance requirements from health authorities, including extensive testing and validation protocols that can lead to delays and increased costs. Additionally, fluctuations in public health policies and the complexities of intellectual property rights can hinder collaboration between manufacturers and pharmaceutical firms. The increasing demand for high-quality standards also pressures manufacturers to invest heavily in advanced technology and skilled workforce, creating barriers for smaller firms and limiting market entry for new players.

Market Trends of the Global Vaccine Contract Manufacturing Market

The global vaccine contract manufacturing market is experiencing a significant trend toward the adoption of modular and flexible manufacturing facilities, enabling enhanced agility and scalability. Providers are increasingly utilizing modular cleanrooms, prefabricated units, and single-use bioreactors to meet diverse production demands and ensure rapid response to market fluctuations. This strategic shift supports multi-product manufacturing capabilities, allowing companies to optimize operations and reduce time-to-market for new vaccines. The trend reflects a broader industry commitment to innovation and efficiency, positioning contract manufacturers to better navigate evolving public health needs and the dynamic landscape of vaccine development.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Vaccine Contract Manufacturing Market Size by Phase & CAGR (2026-2033)

• Market Overview
• Preclinical
• Clinical
• Commercial

Global Vaccine Contract Manufacturing Market Size by Application & CAGR (2026-2033)

• Market Overview
• Human Use
• Veterinary

Global Vaccine Contract Manufacturing Market Size by Workflow & CAGR (2026-2033)

• Market Overview
• Downstream
• Upstream
• Others

Global Vaccine Contract Manufacturing Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Attenuated
• Inactivated
• Subunit-based
• Toxoid-based
• DNA-based

Global Vaccine Contract Manufacturing Market Size by Type & CAGR (2026-2033)

• Market Overview
• Viral
• Bacterial
• Others

Global Vaccine Contract Manufacturing Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Single Vaccines
• Combination Vaccines

Global Vaccine Contract Manufacturing Market Size by End User & CAGR (2026-2033)

• Market Overview
• Biopharmaceutical Companies
• Research Academies & Government Institutes

Global Vaccine Contract Manufacturing Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Fill-Finish
• Bulk Products

Global Vaccine Contract Manufacturing Market Size & CAGR (2026-2033)

• North America (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
  • US
  • Canada
• Europe (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Diosynth Biotechnologies (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDT Biologika GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim BioXcellence (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CordenPharma (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KBI Biopharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia Global, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siegfried Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novasep (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Richter-Helm BioLogics GmbH & Co. KG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syngene International Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations